

(12) UK Patent Application

(19) GB

(11) 2 251 187 A (13)

(43) Date of printing by UK Office 01.07.1992

(21) Application No 9202615.2  
(22) Date of filing 10.08.1990  
(30) Priority data  
(31) 8918232 (32) 10.08.1989 (33) GB  
(86) International application data  
PCT/US90/04434 En 10.08.1990  
(87) International publication data  
WO91/01755 En 21.02.1991

(71) Applicant  
Celltech Limited  
  
(Incorporated in the United Kingdom)  
  
216 Bath Road, Slough, Berkshire, SL1 4EN,  
United Kingdom  
(72) Inventors  
Mark William Bowmer  
Stephen M. Opal  
Jerald C Sadoff  
(74) Agent and/or Address for Service  
Carpmaels & Ransford  
43 Bloomsbury Square, London, WC1A 2RA,  
United Kingdom

(51) INT CL<sup>5</sup>  
A61K 39/40 // (A61K 39/40 39:395)  
(52) UK CL (Edition K)  
A5B BAA B134  
U1S S2410 S2419  
(56) Documents cited by ISA  
GB 2186592 A EP 0374510 A EP 0355067 A  
WO 90/00902 A  
The Journal of Infectious Diseases, volume 1-12 159,  
no. 6, June 1989, Pages 1073-1082.  
J. Clin. Invest, Volume 81, no. 6, June 1988,  
1-12 pages 1925-1937.  
(58) Field of search by ISA  
INT CL<sup>5</sup> A61K

(54) Pharmaceutical product for the treatment of sepsis

(57) An antibody to tumour necrosis factor- $\alpha$  (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each of the components are therefore of utility in therapy of sepsis. The anti-LPS antibody included may be specific for the O-specific chain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognises the core glycolipid of lipopolysaccharide.

GB 2 251 187 A